ICD-10: C83.80

ICD-10 code C83.80 refers to "Other non-follicular lymphoma, unspecified site." This classification falls under the broader category of non-Hodgkin lymphoma (NHL), which encompasses a diverse group of blood cancers that originate in the lymphatic system. Below is a detailed clinical description and relevant information regarding this specific code.

Clinical Description

Definition

Non-follicular lymphoma is a type of non-Hodgkin lymphoma that does not arise from follicle center (germinal center) B-cells. Instead, it includes various subtypes of lymphomas that can originate from different types of lymphoid tissue. The term "other" indicates that the lymphoma does not fit into the more commonly recognized categories, such as diffuse large B-cell lymphoma or mantle cell lymphoma.

Characteristics

• Histological Variability: Non-follicular lymphomas can exhibit a wide range of histological features, which may include small cell, large cell, or mixed cell types. The specific characteristics can influence the clinical behavior and treatment response.
• Clinical Presentation: Patients may present with lymphadenopathy (swollen lymph nodes), splenomegaly (enlarged spleen), or extranodal involvement, where the lymphoma affects organs outside the lymphatic system. Symptoms can also include fever, night sweats, and weight loss, commonly referred to as "B symptoms."
• Diagnosis: Diagnosis typically involves a combination of imaging studies (such as CT scans), biopsy of affected lymph nodes or tissues, and histopathological examination to determine the specific type of lymphoma.

Treatment Options

Treatment for non-follicular lymphoma varies based on the specific subtype, stage of the disease, and patient factors. Common treatment modalities include:
- Chemotherapy: Often the first line of treatment, especially for aggressive forms of lymphoma.
- Radiation Therapy: May be used in localized disease or as a palliative measure.
- Targeted Therapy: Newer treatments that target specific pathways involved in lymphoma cell growth.
- Immunotherapy: Treatments that enhance the immune system's ability to fight cancer, such as monoclonal antibodies.

Coding and Billing Considerations

Importance of Accurate Coding

Accurate coding is crucial for proper billing and reimbursement in healthcare settings. The use of C83.80 allows healthcare providers to specify that the patient has a non-follicular lymphoma without a defined site, which can impact treatment decisions and insurance coverage.

Related Codes

• C83.81: Other non-follicular lymphoma, lymph nodes of head, face, and neck.
• C83.89: Other non-follicular lymphoma, other sites.

Documentation Requirements

To support the use of ICD-10 code C83.80, healthcare providers should ensure thorough documentation that includes:
- Patient history and presenting symptoms.
- Results from imaging studies and biopsies.
- Treatment plans and responses to therapy.

Conclusion

ICD-10 code C83.80 is essential for classifying cases of non-follicular lymphoma that do not have a specified site. Understanding the clinical characteristics, treatment options, and coding implications is vital for healthcare providers managing patients with this type of lymphoma. Accurate documentation and coding not only facilitate appropriate patient care but also ensure compliance with billing requirements.

The ICD-10 code C83.80 refers to "Other non-follicular lymphoma, unspecified site," which encompasses a variety of lymphomas that do not fall under the more commonly recognized categories, such as follicular lymphoma. Understanding the clinical presentation, signs, symptoms, and patient characteristics associated with this diagnosis is crucial for effective management and treatment.

Clinical Presentation

Overview of Non-Follicular Lymphoma

Non-follicular lymphomas are a diverse group of hematological malignancies that arise from lymphoid tissue. They can be aggressive or indolent and may present in various anatomical locations, including lymph nodes, spleen, liver, and bone marrow. The unspecified site designation indicates that the lymphoma's exact location is not clearly defined at the time of diagnosis.

Common Types

This category may include various subtypes of non-Hodgkin lymphoma (NHL), such as:
- Diffuse Large B-Cell Lymphoma (DLBCL): The most common subtype of NHL, often aggressive.
- Mantle Cell Lymphoma: Typically presents in older adults and can be aggressive.
- Burkitt Lymphoma: A highly aggressive form, often associated with a rapid growth rate.

Signs and Symptoms

General Symptoms

Patients with non-follicular lymphoma may exhibit a range of symptoms, which can vary based on the specific subtype and the extent of disease. Common signs and symptoms include:

• Lymphadenopathy: Swelling of lymph nodes, which may be painless and can occur in various regions, including the neck, armpits, and groin.
• B Symptoms: These include fever, night sweats, and unexplained weight loss, which are indicative of systemic involvement.
• Fatigue: A common complaint among patients, often due to anemia or the metabolic demands of the tumor.
• Abdominal Symptoms: If the lymphoma involves the abdomen, patients may experience pain, fullness, or changes in bowel habits due to lymphadenopathy or organ involvement.
• Skin Manifestations: Some patients may develop skin lesions or rashes, particularly in certain subtypes like cutaneous T-cell lymphoma.

Specific Symptoms by Subtype

• DLBCL: Often presents with rapidly enlarging lymph nodes and may involve extranodal sites such as the gastrointestinal tract or central nervous system.
• Mantle Cell Lymphoma: Patients may present with advanced disease at diagnosis, often with lymphadenopathy and splenomegaly.
• Burkitt Lymphoma: Characterized by a very fast-growing mass, often in the abdomen or jaw, and may present with associated symptoms of bowel obstruction or jaw swelling.

Patient Characteristics

Demographics

• Age: Non-follicular lymphomas can occur at any age, but certain subtypes have specific age distributions. For example, DLBCL is more common in older adults, while Burkitt lymphoma is more prevalent in children and young adults.
• Gender: Some studies suggest a male predominance in certain types of non-Hodgkin lymphoma, including DLBCL and mantle cell lymphoma.

Risk Factors

• Immunocompromised States: Patients with weakened immune systems, such as those with HIV/AIDS or those on immunosuppressive therapy, are at increased risk for developing lymphomas.
• Autoimmune Diseases: Conditions like rheumatoid arthritis or Sjögren's syndrome may predispose individuals to lymphoma.
• Family History: A family history of lymphoma or other hematological malignancies can increase risk.

Comorbidities

Patients may present with various comorbid conditions that can complicate the management of lymphoma, including cardiovascular disease, diabetes, or other malignancies.

Conclusion

The clinical presentation of non-follicular lymphoma, as represented by ICD-10 code C83.80, is characterized by a range of symptoms that can vary significantly based on the specific subtype and the extent of disease. Recognizing the signs and symptoms, along with understanding patient demographics and risk factors, is essential for timely diagnosis and effective treatment. Early intervention can significantly impact patient outcomes, making awareness of these characteristics vital for healthcare providers.

ICD-10 code C83.80 refers to "Other non-follicular lymphoma, unspecified site." This classification falls under the broader category of non-Hodgkin lymphoma (NHL), which encompasses various types of lymphomas that do not originate from follicular (germinal center) cells. Below are alternative names and related terms associated with this specific ICD-10 code.

Alternative Names for C83.80

1. Non-Hodgkin Lymphoma, Other Types: This term is often used to describe various forms of non-Hodgkin lymphoma that do not fit into the more specific categories, including follicular lymphoma.

2. Aggressive Non-Hodgkin Lymphoma: Some non-follicular lymphomas can be aggressive in nature, leading to this alternative descriptor.

3. Diffuse Large B-Cell Lymphoma (DLBCL): While DLBCL is a specific subtype of non-Hodgkin lymphoma, it is sometimes included under the umbrella of "other non-follicular lymphomas" due to its non-follicular origin.

4. Peripheral T-Cell Lymphoma (PTCL): This term refers to a group of aggressive lymphomas that arise from T-cells and can also be categorized under non-follicular lymphomas.

5. Lymphoproliferative Disorders: This broader term encompasses various conditions, including non-follicular lymphomas, characterized by the proliferation of lymphocytes.

Related Terms

1. Lymphoma: A general term for cancers that originate in the lymphatic system, which includes both Hodgkin and non-Hodgkin lymphomas.

2. Non-Hodgkin Lymphoma (NHL): This is the overarching category that includes all types of lymphomas that are not classified as Hodgkin lymphoma.

3. B-Cell Lymphoma: Refers to lymphomas that originate from B-cells, which can include various non-follicular types.

4. T-Cell Lymphoma: Similar to B-cell lymphoma, this term refers to lymphomas originating from T-cells, which can also be classified as non-follicular.

5. Lymphoma, Unspecified: This term may be used in clinical settings when the specific type of lymphoma is not determined, which can include C83.80.

Conclusion

Understanding the alternative names and related terms for ICD-10 code C83.80 is crucial for accurate diagnosis, treatment planning, and coding in medical records. These terms help healthcare professionals communicate effectively about the various forms of non-follicular lymphoma and ensure that patients receive appropriate care based on their specific lymphoma type. If you need further details or specific information about treatment options or prognosis related to this code, feel free to ask!

The diagnosis of ICD-10 code C83.80, which refers to "Other non-follicular lymphoma, unspecified site," involves a comprehensive evaluation based on clinical, laboratory, and imaging findings. Here’s a detailed overview of the criteria typically used for diagnosing this condition:

Clinical Evaluation

Symptoms

Patients may present with a variety of symptoms that can include:
- Lymphadenopathy: Swelling of lymph nodes, which may be painless.
- B symptoms: These include fever, night sweats, and unexplained weight loss.
- Fatigue: Generalized tiredness that is not alleviated by rest.
- Pruritus: Itching without an apparent cause.

Medical History

A thorough medical history is essential, including:
- Previous history of lymphoproliferative disorders.
- Family history of lymphoma or other cancers.
- Exposure to risk factors such as certain infections (e.g., Epstein-Barr virus) or environmental toxins.

Laboratory Tests

Blood Tests

• Complete Blood Count (CBC): To check for anemia, leukopenia, or thrombocytopenia.
• Lactate Dehydrogenase (LDH): Elevated levels can indicate lymphoma activity.

Biopsy

• Tissue Biopsy: A definitive diagnosis often requires a biopsy of the affected lymph node or tissue. Histopathological examination is crucial to differentiate non-follicular lymphoma from other types of lymphoma.
• Immunophenotyping: This process helps identify the specific type of lymphoma by analyzing the surface markers on the cells.

Imaging Studies

Radiological Imaging

• CT Scans: Computed tomography scans of the chest, abdomen, and pelvis can help identify enlarged lymph nodes and other potential sites of disease.
• PET Scans: Positron emission tomography can be used to assess metabolic activity in lymph nodes and other tissues, aiding in staging and diagnosis.

Classification and Staging

WHO Classification

The World Health Organization (WHO) classification of lymphomas is used to categorize non-Hodgkin lymphomas, including non-follicular types. This classification is based on histological features and immunophenotypic characteristics.

Ann Arbor Staging System

The Ann Arbor staging system is often employed to determine the extent of the disease, which is critical for treatment planning. Staging considers the number of lymph node regions involved and whether the disease has spread to other organs.

Conclusion

The diagnosis of ICD-10 code C83.80 involves a multifaceted approach that includes clinical assessment, laboratory tests, imaging studies, and histopathological evaluation. Accurate diagnosis is essential for determining the appropriate treatment strategy and prognosis for patients with non-follicular lymphoma. If you have further questions or need more specific information, feel free to ask!

When addressing the standard treatment approaches for ICD-10 code C83.80, which refers to "Other non-follicular lymphoma, unspecified site," it is essential to understand the broader context of non-Hodgkin lymphoma (NHL) and the specific characteristics of this subtype. Non-follicular lymphomas encompass a variety of aggressive and indolent lymphomas that do not fall under the follicular category, and treatment strategies can vary significantly based on the specific type, stage, and patient factors.

Overview of Non-Follicular Lymphoma

Non-follicular lymphomas include several subtypes, such as diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, and others. These lymphomas can be aggressive and may require prompt treatment. The choice of treatment is influenced by factors such as the lymphoma subtype, the stage of the disease, the patient's overall health, and their preferences.

Standard Treatment Approaches

1. Chemotherapy

Chemotherapy remains a cornerstone of treatment for many types of non-follicular lymphoma. Common regimens include:

• R-CHOP: This is a combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. It is particularly effective for DLBCL and is often the first-line treatment for aggressive non-follicular lymphomas[1].
• Other Regimens: Depending on the specific subtype, other chemotherapy regimens may be employed, such as EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) for certain aggressive lymphomas[2].

2. Targeted Therapy

Targeted therapies have become increasingly important in the treatment of non-follicular lymphomas. These therapies focus on specific molecular targets associated with cancer cells:

• Ibrutinib (Imbruvica): This is a Bruton's tyrosine kinase inhibitor used primarily for mantle cell lymphoma and other B-cell malignancies. It is often used in relapsed or refractory cases[3].
• Other Agents: Other targeted therapies may include agents like venetoclax, which is used for specific types of B-cell lymphomas, particularly those with certain genetic mutations[4].

3. Immunotherapy

Immunotherapy has shown promise in treating various lymphomas:

• Rituximab: This monoclonal antibody targets CD20 on B-cells and is commonly used in combination with chemotherapy for many B-cell lymphomas, including non-follicular types[5].
• CAR T-cell Therapy: For relapsed or refractory cases, CAR T-cell therapies such as Kymriah (tisagenlecleucel) and Breyanzi (lisocabtagene maraleucel) have been approved and can be effective in treating aggressive non-follicular lymphomas[6][7].

4. Radiation Therapy

Radiation therapy may be used in certain situations, particularly for localized disease or as a palliative measure to relieve symptoms. It is less commonly used as a primary treatment for systemic non-follicular lymphomas but can be effective in specific cases[8].

5. Stem Cell Transplantation

For eligible patients, especially those with aggressive forms of non-follicular lymphoma, autologous stem cell transplantation may be considered after initial chemotherapy. This approach can provide a chance for long-term remission, particularly in younger patients or those with high-risk disease[9].

Conclusion

The treatment of non-follicular lymphoma (ICD-10 code C83.80) is multifaceted and tailored to the individual patient based on the specific characteristics of the lymphoma and the patient's overall health. Standard approaches typically involve a combination of chemotherapy, targeted therapies, immunotherapy, and, in some cases, radiation or stem cell transplantation. Ongoing research continues to refine these treatment strategies, aiming to improve outcomes for patients with this complex group of diseases. For the most effective treatment plan, consultation with a hematologist or oncologist specializing in lymphomas is crucial.